Questions and Answers

What is PCA3?
What is the PCA3 test?
What is the difference between the PCA3 test and PSA?
What is the most important advantage of the PCA3 test?
When should I use a PCA3 test?
Does the PCA3 Score only help in deciding whether a biopsy is needed or can it also aid in differentiating significant (aggressive) from insignificant (indolent) cancer?
Can the PCA3 Assay be used to monitor progression of prostate cancer during active surveillance?
Can the PCA3 test be used to monitor disease response and/or recurrence of prostate cancer after local or systemic therapy?
How will the PCA3 test be done?
What is the PCA3 Score?
What is the PCA3 Score?
What does the PCA3 Score mean?
How should the PCA3 Score be interpreted?
How would you explain the value of the PCA3 test for a patient?
Which physician should I consult to perform a PCA3 test?
Can every urologist perform the PCA3 test?
How long do I have to wait for the result of the PCA3 test?
How much does the PCA3 test cost and is the PCA3 test covered by health insurances?
Does the volume of the urine sample that is collected for the PCA3 test influence the PCA3 Score?
5α-reductase inhibitors, such as finasteride and dutasteride, decrease the size of the prostate and the serum PSA level. Do these agents also impact on the PCA3 Score?
Is the PCA3 Score age-dependent?
Does testosterone replacement therapy influence the PCA3 Score?
Is the PCA3 test affected by the presence of a urinary tract infection?
Does recent ejaculation affect the PCA3 score?
Does treatment with antibiotics influence the PCA3 Score?
Can the PCA3 test aid in the decision whether a biopsy is needed in men suspected of having prostate cancer but who have been previously treated for prostatitis?
Can the PCA3 test aid in the decision whether a biopsy is needed in men suspected of having prostate cancer but who have previously undergone transurethral resection of the prostate (TURP) for benign prostatic hyperplasia (BPH)?
Can the PCA3 Score aid in the decision to perform a prostate biopsy in men who have known genetic variations linked to an increased prostate cancer risk (e.g. a BRCA2 mutation) either themselves or in their immediate family?
Would the PCA3 test be a good option for men with a high prostate specific antigen (PSA) level and an enlarged prostate who have had a colostomy, i.e. in whom a prostate biopsy by means of a rectal approach can not be performed?
Can the PCA3 Score aid in the decision to perform a biopsy in a relatively young patient, with no family history of prostate cancer, a normal digital rectal examination (DRE) and a serum prostate specific antigen level (PSA) at or slightly higher than normal for his age?
Can the PCA3 Score be used to aid in the decision to perform a biopsy of a patient without a family history of prostate cancer, a normal digital rectal examination and a moderately elevated (low-moderately high) serum prostate specific antigen (PSA) level (e.g. 9.1 ng/mL at an age of 69 years)?
What are the current problems in the diagnosis of early organ-confined prostate cancer?
What are the most interesting features of the first gene-based marker for prostate cancer?
What are currently the main problems in diagnosing prostate cancer?
How was the PCA3 gene discovered?